Effects of salbutamol and phlorizin on acute pulmonary inflammation and disease severity in experimental sepsis

PLoS One. 2019 Sep 19;14(9):e0222575. doi: 10.1371/journal.pone.0222575. eCollection 2019.

Abstract

Respiratory infection can be exacerbated by the high glucose concentration in the airway surface liquid (ASL). We investigated the effects of salbutamol and phlorizin on the pulmonary function, oxidative stress levels and SGLT1 activity in lung, pulmonary histopathological damages and survival rates of rats with sepsis. Sepsis was induced by cecal ligation and puncture surgery (CLP). Twenty-four hours after surgery, CLP rats were intranasally treated with saline, salbutamol or phlorizin. After 2 hours, animals were anesthetized and sacrificed. Sepsis promoted atelectasis and bronchial inflammation, and led to increased expression of SGLT1 on cytoplasm of pneumocytes. Salbutamol treatment reduced bronchial inflammation and promoted hyperinsuflation in CLP rats. The interferon-ɤ and Interleucin-1β concentrations in bronchoalveolar lavage (BAL) were closely related to the bronchial inflammation regulation. Salbutamol stimulated SGLT1 in plasma membrane; whereas, phlorizin promoted the increase of SGLT1 in cytoplasm. Phlorizin reduced catalase activity and induced a significant decrease in the survival rate of CLP rats. Taken together, sepsis promoted atelectasis and lung inflammation, which can be associated with SGLT1 inhibition. The loss of function of SGLT1 by phlorizin are related to the augmented disease severity, increased atelectasis, bronchial inflammation and a significant reduction of survival rate of CLP rats. Alternatively salbutamol reduced BAL inflammatory cytokines, bronchial inflammation, atelectasis, and airway damage in sepsis. These data suggest that this selective β2-adrenergic agonist may protect lung of septic acute effects.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury / drug therapy*
  • Acute Lung Injury / metabolism
  • Albuterol / pharmacology*
  • Alveolar Epithelial Cells / drug effects
  • Alveolar Epithelial Cells / metabolism
  • Animals
  • Bronchoalveolar Lavage Fluid
  • Cytokines / metabolism
  • Cytoplasm / drug effects
  • Cytoplasm / metabolism
  • Disease Models, Animal
  • Lung / drug effects
  • Lung / metabolism
  • Male
  • Oxidative Stress / drug effects
  • Phlorhizin / pharmacology*
  • Pneumonia / drug therapy*
  • Pneumonia / metabolism
  • Rats
  • Rats, Wistar
  • Sepsis / drug therapy*
  • Sepsis / metabolism
  • Severity of Illness Index
  • Sodium-Glucose Transporter 1 / metabolism

Substances

  • Cytokines
  • Sodium-Glucose Transporter 1
  • Phlorhizin
  • Albuterol

Grants and funding

This research was supported by a grant from CNPq, CAPES, Federal University of Uberlandia and FAPEMIG. Our best regards to National Institute of Science and Technology in Theranostics and Nanobiotechnology (CNPq Process N.: 465669/2014-0). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.